Experts Assess ACS Cancer Screening Recommendations
A new article supports the recent changes made by the American Cancer Society in its recommendations for breast cancer screening. The new recommendations have modified the suggested ages for annual and biannual mammography and have also focused on patient preferences in decision making.
The three primary recommendations by the ASC included:
1. Annual screening to begin at age 45 with no objections to begin as early as 40.
2. Biannual screening starting at age 55 and the option to continue with annual screening if preferred.
3. Discontinued use of clinical breast examinations as a screening mechanism for women at any age.
When it comes to breast cancer screening practices, it is important to have a delicate balance between the dangers of insufficient monitoring and unnecessary testing. The primary dangers of insufficient monitoring are failing to know if a woman has cancer and delaying treatment while the dangers of unnecessary testing include an increased exposure to radiation and unnecessary false positives.
The article talks about the important differences between the sensitivity and false positive rates for mammography. While mammography detects 84 percent of breast cancers in asymptomatic women, nearly 95 percent of all positive mammograms are false positives.
"Our goal was to caution asymptomatic women that positive mammograms are vastly more likely to be false positives than actual evidence of cancer," said Dr. William Skorupski, co-author of the Significance article. "For most women, a false positive mammogram is about 19 times more likely than a true positive," added co-author Dr. Howard Wainer.
Image Credit: Wikimedia Commons
Published on : Tue, 9 Aug 2016
THE VEVO MD IS THE WORLD’S FIRST ULTRA HIGH FREQUENCY ULTRASOUND SYSTEM DESIGNED FOR CLINICAL USE WITH FREQUENCIES UP TO 70 MHz. This groundbreaking technology opens up new possibilities for medical imaging that have never been seen before. Whether...
Powered by the most revolutionary ZONE Sonography® Technology, Resona 7’s new ZST+ platform brings the ultrasound image quality to a higher level by zone acquisition and channel data processing. Resona 7 also provides clinical research with the revolutionary...
Remarkable image quality, right at the point of care. The Trident system revolutionizes breast tissue imaging by incorporating a micro-focused tube, unique specimen image processing algorithms and amorphous selenium direct digital detector. The...
The SonoSite EDGE II is a high-resolution, all-digital, 9.0-pound (4.1 kg) ultrasound system with a 12.1in. LED full-bleed glass display. The Edge II boosts improvements in cardiac and abdominal image quality through DirectClear Technology and a new...
A breakthrough in biopsy efficiency The Brevera system streamlines the entire breast biopsy process from start to finish – with real-time imaging for instant verification and automated post-biopsy specimen handling. This has the potential to...